The prevalence and clinical spectrum of post-Covid syndrome in patients with rheumatic diseases: a single-center experience

Post-coronavirus disease (COVID) syndrome (PCS) is a term used to describe the clinical condition of patients who have recovered from COVID-19 but are still experiencing prolonged effects of infection or persistent symptoms for longer than expected. Although PCS has been previously studied in the ge...

Full description

Saved in:
Bibliographic Details
Main Authors: S. Batıbay (Author), R. Koçak Ulucaköy (Author), Z. Günendi (Author), F. Göğüş (Author)
Format: Book
Published: PAGEPress Publications, 2022-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d09dded1f9da4aa1a30e8830a656a81d
042 |a dc 
100 1 0 |a S. Batıbay  |e author 
700 1 0 |a R. Koçak Ulucaköy  |e author 
700 1 0 |a Z. Günendi  |e author 
700 1 0 |a F. Göğüş  |e author 
245 0 0 |a The prevalence and clinical spectrum of post-Covid syndrome in patients with rheumatic diseases: a single-center experience 
260 |b PAGEPress Publications,   |c 2022-05-01T00:00:00Z. 
500 |a 10.4081/reumatismo.2022.1481 
500 |a 0048-7449 
500 |a 2240-2683 
520 |a Post-coronavirus disease (COVID) syndrome (PCS) is a term used to describe the clinical condition of patients who have recovered from COVID-19 but are still experiencing prolonged effects of infection or persistent symptoms for longer than expected. Although PCS has been previously studied in the general population, it has not been investigated in a specific population of patients with inflammatory rheumatic disease (IRD). This study aims to evaluate the presence and frequency of PCS among our rheumatology outpatients. This is a cross-sectional study of patients with IRD whose symptoms persisted for 12 weeks after the detection of COVID-19 infection. The patients were assessed with a survey form during their routine clinic follow-up or by contacting them by phone. Patients' demographics, diagnosis, medication, comorbidities, outcome of COVID-19, and symptoms related to PCS were collected. Fifty-three patients with IRD and COVID (mean age: 48.5 13.99 years, 71.7% women) were included. PCS was observed in 36 (67.9%) patients. Twenty-two (41.5%) of them had three or more symptoms; 14 (26.4%) had one or two symptoms. Although more than 30 symptoms were detected, the most frequent were fatigue and weakness. No significant relationship was detected between the development of PCS and gender, age, disease duration, presence of COVID-related complications, and the need for oxygen support, except for smoking which showed a protective effect (p=0.008). PCS was detected in more than half of the patients. There was no independent risk factor for the development of PCS, except smoking. 
546 |a EN 
546 |a IT 
690 |a COVID-19 
690 |a post COVID-19 syndrome 
690 |a rheumatology 
690 |a long COVID 
690 |a inflammatory rheumatic disease. 
690 |a Medicine 
690 |a R 
690 |a Internal medicine 
690 |a RC31-1245 
655 7 |a article  |2 local 
786 0 |n Reumatismo, Vol 74, Iss 1 (2022) 
787 0 |n https://www.reumatismo.org/index.php/reuma/article/view/1481 
787 0 |n https://doaj.org/toc/0048-7449 
787 0 |n https://doaj.org/toc/2240-2683 
856 4 1 |u https://doaj.org/article/d09dded1f9da4aa1a30e8830a656a81d  |z Connect to this object online.